Midterm 2026/2027 | Chamberlain University
Practice Questions, Correct Answers & Exam
Review
NR566 ADVANCED PHARMACOLOGY WEEK 4 MIDTERM 2026/2027
CHAMBERLAIN UNIVERSITY PRACTICE QUESTIONS
DOCUMENT OVERVIEW
• This comprehensive question study guide is designed to assess mastery of
advanced pharmacological concepts, mechanisms of action, clinical applications,
and critical safety considerations across all major drug classes covered in Week 4.
• Use this material by working through questions systematically, reviewing
rationales for both correct and incorrect options to strengthen your clinical
reasoning and pharmacological foundation before the midterm examination.
QUESTION 1
A 52-year-old male with hypertension is started on lisinopril, an ACE inhibitor.
After 2 weeks, he reports a persistent dry cough. What is the most likely
mechanism for this adverse effect?
A) Increased aldosterone secretion causing airway irritation
B) Direct bronchial smooth muscle constriction
C) Accumulation of bradykinin in the lungs leading to cough reflex stimulation
D) Inhibition of angiotensin II receptors on bronchial tissue
E) Increased norepinephrine activity in the respiratory center
✓ CORRECT ANSWER: C) Accumulation of bradykinin in the lungs leading to
cough reflex stimulation
,RATIONALE: ACE inhibitors block the conversion of angiotensin I to angiotensin II,
but ACE also breaks down bradykinin, a potent inflammatory mediator. When ACE
is inhibited, bradykinin accumulates in tissues, including the lungs, where it
stimulates cough receptors. This dry cough occurs in 10-20% of patients on ACE
inhibitors and is a known class effect. The cough typically appears within 1-2 weeks
of starting the medication and resolves within days to weeks after discontinuation.
This is distinct from the bronchoconstriction seen with beta-blockers and is not
related to angiotensin II blockade or aldosterone effects.
QUESTION 2
A 68-year-old female with chronic kidney disease (CKD Stage 3b) is prescribed
metformin for type 2 diabetes. Which pharmacokinetic consideration is most
important for this patient?
A) Increased hepatic metabolism requires dose reduction
B) Impaired renal clearance increases risk of lactic acidosis
C) Enhanced absorption in the GI tract requires lower doses
D) Increased protein binding reduces drug efficacy
E) Shortened half-life necessitates more frequent dosing
✓ CORRECT ANSWER: B) Impaired renal clearance increases risk of lactic
acidosis
RATIONALE: Metformin is renally eliminated unchanged, and in patients with CKD,
reduced glomerular filtration leads to drug accumulation. This increases the risk of
metformin-associated lactic acidosis (MALA), a rare but serious adverse effect.
Current guidelines recommend avoiding metformin or using caution when eGFR is
30-45 mL/min/1.73m² (CKD Stage 3b) and contraindicate it when eGFR is <30. Dose
adjustments are necessary based on renal function. Metformin is not significantly
hepatically metabolized, does not undergo protein binding issues, and does not
have altered absorption in renal disease. The half-life does not shorten; clearance is
prolonged.
,QUESTION 3
A 45-year-old male with a history of myocardial infarction is prescribed a
beta-blocker. After initiation, he experiences erectile dysfunction. What is the
pharmacological basis for this adverse effect?
A) Alpha-1 adrenergic antagonism causing vasodilation
B) Beta-2 adrenergic blockade reducing smooth muscle relaxation in corpus
cavernosum
C) Increased parasympathetic activity
D) Direct inhibition of phosphodiesterase-5 enzyme
E) Dopamine antagonism in the hypothalamus
✓ CORRECT ANSWER: B) Beta-2 adrenergic blockade reducing smooth muscle
relaxation in corpus cavernosum
RATIONALE: Erectile function requires relaxation of smooth muscle in the corpus
cavernosum, a process mediated by beta-2 adrenergic receptors. Non-selective
beta-blockers (like propranolol, nadolol) and even cardioselective beta-1 blockers
(at higher doses) can block beta-2 receptors, impairing penile smooth muscle
relaxation and causing erectile dysfunction. This is a well-documented adverse
effect occurring in 10-15% of male patients. Alpha-1 antagonism would improve,
not impair, erectile function. Parasympathomimetic effects would enhance
erection. Phosphodiesterase-5 inhibition would improve erectile function. Beta-
blockers have no dopaminergic effects.
QUESTION 4
A 34-year-old female with bipolar disorder is maintained on lithium.
Laboratory values show a serum lithium level of 1.2 mEq/L. She is now
prescribed a thiazide diuretic for hypertension. What pharmacokinetic
interaction is most likely to occur?
, A) Decreased lithium absorption in the GI tract
B) Increased hepatic metabolism of lithium
C) Increased renal reabsorption of lithium leading to toxicity
D) Enhanced protein binding reducing lithium efficacy
E) Increased glomerular filtration of lithium
✓ CORRECT ANSWER: C) Increased renal reabsorption of lithium leading to
toxicity
RATIONALE: Lithium is renally cleared via glomerular filtration and is reabsorbed in
the proximal tubule alongside sodium. Thiazide diuretics cause volume depletion
and hyponatremia, which enhances proximal tubule reabsorption of lithium
(proximal tubule reabsorption follows sodium). This reduces renal lithium
clearance, causing serum levels to rise and potentially leading to lithium toxicity
(tremor, confusion, ataxia, cardiac arrhythmias). Loop diuretics have a similar
effect. NSAIDs also reduce lithium clearance. When thiazides are necessary, lithium
dose reduction (by 25-50%) and careful monitoring of serum levels are required.
Lithium is not hepatically metabolized and does not undergo protein binding.
QUESTION 5
A 71-year-old male with congestive heart failure is taking digoxin. His serum
potassium is found to be 3.0 mEq/L (normal 3.5-5.0). What is the primary
concern with this electrolyte abnormality?
A) Increased urinary excretion of digoxin
B) Enhanced Na+/K+-ATPase inhibition by digoxin increasing toxicity risk
C) Decreased absorption of digoxin in the GI tract
D) Activation of the renin-angiotensin-aldosterone system
E) Increased protein binding of digoxin
✓ CORRECT ANSWER: B) Enhanced Na+/K+-ATPase inhibition by digoxin
increasing toxicity risk